Novonesis Delivers Strong Full-Year Results and Expects Continued Growth in 2025

Novonesis A/S, a leading global biosolutions partner, has reported robust financial results for the 12-month period ending December 31, 2024, and provided an outlook for 2025. The company's strong performance reflects its commitment to sustainability, innovation, and addressing global challenges through its biosolutions portfolio.

In 2024, Novonesis delivered an 8% organic sales growth and an adjusted EBITDA margin of 36.1%. This impressive performance was driven by both Food & Health Biosolutions and Planetary Health Biosolutions, with specific sectors contributing significantly to this growth:

1. Food & Beverages: This sector grew 8% organically, driven by strong growth in Dairy and solid development in Baking. This growth can be attributed to the increasing demand for healthier and more sustainable food options, which aligns with Novonesis' biosolutions portfolio.
2. Household Care: This sector grew 13% organically, driven by increased penetration, innovation, and pricing. The strong performance in this sector can be linked to the growing consumer preference for eco-friendly and sustainable cleaning products, which Novonesis caters to through its biosolutions.
3. Energy: This sector grew 6% organically, mainly driven by double-digit growth in Energy. This growth can be attributed to the increasing demand for renewable energy sources and the need for more efficient energy production processes, which Novonesis' biosolutions help address.



Novonesis' commitment to sustainability and positive impact on the UN Sustainable Development Goals (SDGs) has been a significant driver of its growth and investment potential. In 2024, 83% of Novonesis' sales were documented and aligned with six UN SDGs. Furthermore, the company has reduced its Scope 1 and 2 CO2 emissions by 63% compared to 2018 while increasing revenue by more than 25% in the same period. This focus on sustainability helps Novonesis address customers' and the world's most pressing challenges, aligning with its long-term strategic objectives.

For 2025, Novonesis expects continued strong performance, with a relatively stronger first half. Pro forma organic sales growth is expected to be at 5-8% (6-9% excluding the exit from certain countries), including sales synergies and pricing. The adjusted EBITDA margin is expected to be at 37-38% including significant growth re-investments. Planetary Health Biosolutions as well as Food & Health Biosolutions are both expected to grow within the Group level range.

Novonesis' commitment to innovation and new product development has also been a key driver of its growth. The company launched 45 new innovations during 2024, with around 30% of its sales coming from products introduced in the past five years. This commitment to innovation and sustainable product development can drive long-term growth and create new revenue streams.

In conclusion, Novonesis' strong full-year results and positive outlook for 2025 reflect the company's commitment to sustainability, innovation, and addressing global challenges through its biosolutions portfolio. The company's focus on sustainability, alignment with UN SDGs, and commitment to innovation make it an attractive investment opportunity for socially responsible investors seeking steady growth and positive impact.